AstraZeneca PLC (AZN): Rega marang bathi kanthi panyesuaian wutah

A stable geopolitical backdrop and humanitarian status protect AstraZeneca PLC (AZN) assets from trade conflicts. The behemoth is betting on costly R&D in molecular biology to combat cancer. High medical authority confirms its status as an oncology flagship. The historical PEG level demonstrates valuation dynamics, where 1.50 serves as the current metric, determining the company's investment attractiveness.

AstraZeneca Corp. - Pangali PEG AZN (periode 04.07.2022 - 10.11.2026)

Rincian metrik lan analitis perusahaan AstraZeneca PLC (AZN)

- rega saham lan konsensus proyeksi valuasi:

Bagan owah-owahan rega AstraZeneca Plc|AZN - Bagan rega target

- data kapitalisasi bursa:

Nilai pasar AstraZeneca AB|AZN - Nilai Total Perusahaan

- data nilai buku modal saham:

Aset Bersih saben Siji Saham AstraZeneca|AZN - Kapitalisasi Buku|Rasio Kapitalisasi marang Nilai Buku astrazeneca.com|AZN - Total Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

Koefisien Total Utang marang Modal AstraZeneca PLC|AZN - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal astrazeneca.com|AZN - Gunggung utang perusahaan|Utang marang aset resik AstraZeneca AB|AZN - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan AstraZeneca|Koefisien jangkoan perantara astrazeneca.com

- rincian asil keuangan lan kelipatan valuasi:

AZN - Penghasilan resik|Bathi resik mangsa ngarep AstraZeneca PLC|AZN - Rasio rega marang bathi|Pangali mangsa ngarep rega marang bathi AstraZeneca Corp.|AZN - Pangali PEG|Pangali EV/EBITDA AstraZeneca AB|AZN - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben siji saham sajrone 12 wulan pungkasan AstraZeneca|AZN - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan astrazeneca.com|AZN - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep AstraZeneca PLC

Analisis umum perusahaan:AstraZeneca PLC

The PEG ratio compares a stock's market value with net income dynamics, allowing investors to determine the extent of overpayment for future business growth. For AstraZeneca PLC (AZN), with its patent-protected R&D pipeline in oncology, this P/E to earnings growth ratio serves as an indicator of how effectively innovative blockbusters are capitalized, where values below one signal a fundamental undervaluation of the asset.

Perusahaan pesaing

LLY (Lilly) - Koefisien bali modal nimbang wutah|Rasio rega marang bathi tumrap wutah Abbvie ABBV|Novartis Pharma (NVS) - Rega marang bathi kanthi panyesuaian wutah|MRK - Rasio rega marang bathi tumrap wutah|NVO: Rasio rega marang bathi tumrap wutah|AMGN: Pangali PEG|Rasio P/E diaturake wutah PFE|SNY (Sanofi Aventis) - Pangali PEG|Bristol-Myers Squibb Co. (BMY) - Kapitalisasi marang bathi resik kanthi nimbang wutah|Rasio rega marang bathi tumrap wutah GSK plc (GSK)|takeda.com - Rasio P/E diaturake wutah|Pangali PEG TEVA (Teva Pharmaceutical Industries Limited)|Rasio rega marang wutah bathi resik Dr. Reddy's Laboratories Limited|Viatris Corp - Pangali PEG|ROIV - Pangali PEG|Zai Lab Limited (ZLAB) - Rasio rega marang bathi tumrap wutah|BHC - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali rega marang bathi tumrap wutah COSM